Pramlintide: Side Effects, Uses & Monitoring
Facts extracted from current FDA product labeling for Pramlintide. Educational only — not medical advice.
Labeled uses
SYMLIN is indicated as an adjunctive treatment in patients with type 1 or type 2 diabetes who use mealtime insulin therapy and who have failed to achieve desired glucose control despite optimal insulin therapy.
Source: FDA labeling via NIH DailyMed (set 4aea30ff…). Not affiliated with FDA or NIH.
Medical disclaimer: Always consult a qualified healthcare professional about any medication.